Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:KIN
- CUSIP: N/A
- Web: www.kindredbio.com
- Market Cap: $197.65 million
- Outstanding Shares: 27,838,000
- 50 Day Moving Avg: $7.66
- 200 Day Moving Avg: $7.02
- 52 Week Range: $3.90 - $9.65
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.89
- P/E Growth: -0.14
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $3.07 per share
- Price / Book: 2.20
- EBIDTA: ($24,990,000.00)
- Return on Equity: -37.00%
- Return on Assets: -35.40%
- Current Ratio: 29.87%
- Quick Ratio: 29.87%
- Average Volume: 234,934 shs.
- Beta: 0.18
- Short Ratio: 2.64
Frequently Asked Questions for Kindred Biosciences (NASDAQ:KIN)
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences, Inc. (NASDAQ:KIN) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. View Kindred Biosciences' Earnings History.
Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?
5 equities research analysts have issued twelve-month target prices for Kindred Biosciences' stock. Their predictions range from $7.50 to $10.50. On average, they expect Kindred Biosciences' stock price to reach $9.00 in the next year. View Analyst Ratings for Kindred Biosciences.
Are investors shorting Kindred Biosciences?
Kindred Biosciences saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 714,173 shares, a decrease of 29.0% from the July 14th total of 1,005,956 shares. Based on an average daily trading volume, of 242,575 shares, the days-to-cover ratio is currently 2.9 days. Currently, 2.8% of the company's shares are sold short.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include G1 THERAPEUTICS (GTHX), AVEO Pharmaceuticals (AVEO), Adaptimmune Therapeutics PLC (ADAP), MERSANA THERPTS (MRSN), Selecta Biosciences (SELB), GlycoMimetics (GLYC), RA PHARMCTL INC (RARX), BioCryst Pharmaceuticals (BCRX), Edge Therapeutics (EDGE), Geron Corporation (GERN), BioSpecifics Technologies Corp (BSTC), Corbus Pharmaceuticals Holdings (CRBP), BioTime (BTX), Merus N.V. (MRUS), Rigel Pharmaceuticals (RIGL), CymaBay Therapeutics (CBAY), Minerva Neurosciences (NERV) and Oxford BioMedica plc (OXB).
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Wendy Wee, Chief Financial Officer
- Denise M. Bevers, Chief Operating Officer, Secretary
- Stephen Sundlof Ph.D., Executive Vice President - Regulatory Affairs and Quality, Chief Scientific Officer
- Herbert D. Montgomery, Independent Director
- Raymond Townsend, Independent Director
- Ervin Veszpremi, Independent Director
Who owns Kindred Biosciences stock?
Kindred Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (5.87%), Vanguard Group Inc. (3.20%), EcoR1 Capital LLC (1.96%), Wells Fargo & Company MN (1.42%), AJO LP (1.20%) and State Street Corp (0.92%). Company insiders that own Kindred Biosciences stock include Ernest Mario, Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.
Who sold Kindred Biosciences stock? Who is selling Kindred Biosciences stock?
Kindred Biosciences' stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Prudential Financial Inc., Goldman Sachs Group Inc., Granite Investment Partners LLC and Dimensional Fund Advisors LP. Company insiders that have sold Kindred Biosciences stock in the last year include Park West Asset Management Llc and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.
Who bought Kindred Biosciences stock? Who is buying Kindred Biosciences stock?
Kindred Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including AJO LP, Vanguard Group Inc., State Street Corp, Northern Trust Corp, Citigroup Inc., EAM Investors LLC, TIAA CREF Investment Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Kindred Biosciences stock in the last two years include Ernest Mario, Park West Asset Management Llc and Raymond Townsend. View Insider Buying and Selling for Kindred Biosciences.
How do I buy Kindred Biosciences stock?
Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Kindred Biosciences stock can currently be purchased for approximately $6.75.
Consensus Ratings for Kindred Biosciences (NASDAQ:KIN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 3 Buy Ratings, 1 Strong Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$9.00 (33.33% upside)|
Analysts' Ratings History for Kindred Biosciences (NASDAQ:KIN)
(Data available from 8/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/31/2017||FBR & Co||Reiterated Rating||Buy||Low|
|5/15/2017||BMO Capital Markets||Reiterated Rating||Hold||$8.00||N/A|
|1/3/2017||Feltl & Co.||Reiterated Rating||Strong-Buy||N/A|
|11/1/2016||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy||$7.50||N/A|
Earnings History for Kindred Biosciences (NASDAQ:KIN)Earnings History by Quarter for Kindred Biosciences (NASDAQ KIN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Kindred Biosciences (NASDAQ:KIN)
Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS
Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Kindred Biosciences (NASDAQ:KIN)
Insider Ownership Percentage: 19.10%Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)
Institutional Ownership Percentage: 51.98%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/12/2017||Park West Asset Management Llc||Major Shareholder||Buy||600,000||$7.50||$4,500,000.00|| |
|7/3/2017||Richard Chin||Insider||Sell||13,000||$8.26||$107,380.00|| |
|6/22/2017||Richard Chin||Insider||Sell||13,000||$7.75||$100,750.00|| |
|6/8/2017||Park West Asset Management Llc||Major Shareholder||Buy||15,311||$6.65||$101,818.15|| |
|5/11/2017||Park West Asset Management Llc||Major Shareholder||Buy||155,076||$6.83||$1,059,169.08|| |
|3/15/2017||Park West Asset Management Llc||Major Shareholder||Buy||400,000||$6.60||$2,640,000.00|| |
|3/13/2017||Park West Asset Management Llc||Major Shareholder||Buy||4,200||$6.20||$26,040.00|| |
|3/9/2017||Park West Asset Management Llc||Major Shareholder||Buy||18,066||$6.08||$109,841.28|| |
|1/13/2017||Park West Asset Management Llc||Major Shareholder||Buy||1,690,000||$6.20||$10,478,000.00|| |
|1/9/2017||Park West Asset Management Llc||Major Shareholder||Buy||131,500||$5.30||$696,950.00|| |
|1/6/2017||Park West Asset Management Llc||Major Shareholder||Buy||110,617||$5.10||$564,146.70|| |
|12/16/2016||Park West Asset Management Llc||Insider||Sell||18,000||$4.78||$86,040.00|| |
|12/14/2016||Park West Asset Management Llc||Major Shareholder||Buy||8,334||$4.75||$39,586.50|| |
|12/13/2016||Park West Asset Management Llc||Major Shareholder||Buy||1,148||$4.75||$5,453.00|| |
|12/12/2016||Park West Asset Management Llc||Major Shareholder||Buy||3,112||$4.74||$14,750.88|| |
|3/15/2016||Ernest Mario||Director||Buy||30,000||$3.55||$106,500.00|| |
|11/23/2015||Raymond Townsend||Director||Buy||2,000||$4.00||$8,000.00|| |
|11/18/2015||Raymond Townsend||Director||Buy||2,323||$4.78||$11,103.94|| |
|8/31/2015||Raymond Townsend||Director||Buy||1,677||$5.85||$9,810.45|| |
|8/14/2015||Raymond Townsend||Director||Buy||3,000||$6.04||$18,120.00|| |
|9/29/2014||Oleg Nodelman||Director||Buy||100,000||$9.56||$956,000.00|| |
|9/3/2014||Ernest Mario||Director||Buy||10,000||$10.55||$105,500.00|| |
|8/28/2014||Oleg Nodelman||Director||Buy||47,000||$10.85||$509,950.00|| |
|8/26/2014||Oleg Nodelman||Director||Buy||85,244||$10.50||$895,062.00|| |
|12/12/2013||Kevin Schultz||Insider||Buy||4,000||$7.00||$28,000.00|| |
|12/12/2013||Oleg Nodelman||Director||Buy||400,000||$7.00||$2,800,000.00|| |
|12/12/2013||Stephen Sundlof||SVP||Buy||1,000||$7.00||$7,000.00|| |
Headline Trends for Kindred Biosciences (NASDAQ:KIN)
Latest Headlines for Kindred Biosciences (NASDAQ:KIN)
|Kindred Biosciences, Inc. (KIN) Short Interest Down 29.0% in July|
www.americanbankingnews.com - August 14 at 3:04 AM
|Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - August 8 at 10:40 PM
|Kindred Biosciences, Inc. (NASDAQ:KIN) Releases Quarterly Earnings Results|
www.americanbankingnews.com - August 8 at 11:14 AM
|Edited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT|
finance.yahoo.com - August 8 at 5:40 AM
|Kindred Biosciences Announces Second Quarter 2017 Financial Results|
finance.yahoo.com - August 7 at 7:38 PM
|Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting|
finance.yahoo.com - August 4 at 11:59 PM
| Brokerages Anticipate Kindred Biosciences, Inc. (KIN) Will Post Earnings of -$0.29 Per Share|
www.americanbankingnews.com - August 2 at 10:14 PM
|Kindred Biosciences, Inc. (KIN) Short Interest Update|
www.americanbankingnews.com - July 29 at 7:15 AM
|BRIEF-Kindred Biosciences says board appointed Wendy Wee as CFO - SEC Filing|
www.reuters.com - July 29 at 1:09 AM
|Kindred Biosciences to Announce Second Quarter 2017 Financial Results|
finance.yahoo.com - July 24 at 10:19 AM
|Kindred Biosciences, Inc. (NASDAQ:KIN) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - July 14 at 10:52 PM
|Park West Asset Management Llc Purchases 600,000 Shares of Kindred Biosciences, Inc. (KIN) Stock|
www.americanbankingnews.com - July 14 at 7:59 PM
|KindredBio Announces Pricing of Public Offering|
finance.yahoo.com - July 13 at 6:07 AM
|BRIEF-Kindredbio announces proposed public offering of common stock|
www.reuters.com - July 12 at 1:51 AM
|KindredBio Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - July 12 at 1:51 AM
|Kindred Biosciences, Inc. (NASDAQ:KIN) Expected to Post Earnings of -$0.29 Per Share|
www.americanbankingnews.com - July 11 at 2:28 PM
|Former Boehringer Ingelheim manufacturing plant finds new owner|
www.bizjournals.com - July 7 at 6:46 AM
|Richard Chin Sells 13,000 Shares of Kindred Biosciences, Inc. (KIN) Stock|
www.americanbankingnews.com - July 6 at 8:06 PM
|Will Kindred Biosciences (KIN) Continue to Surge Higher?|
finance.yahoo.com - June 30 at 11:13 PM
|Kindred Biosciences (KIN) Buys Kansas Manufacturing Plant and Reports Execution of Commercial Manufacturing Agreement for Zimeta|
www.streetinsider.com - June 26 at 8:03 PM
|BRIEF-Kindred Biosciences reports acquisition of Kansas manufacturing plant|
www.reuters.com - June 26 at 8:03 PM
|Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for Zimeta|
finance.yahoo.com - June 26 at 8:03 PM
|Kindred Biosciences, Inc. (KIN) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - June 19 at 10:48 PM
|Kindred Biosciences, Inc. (KIN) Rating Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - June 17 at 12:32 AM
|Kindred Biosciences, Inc. (KIN) Research Coverage Started at Aegis|
www.americanbankingnews.com - June 16 at 8:30 AM
|Kindred Biosciences Added to the Russell 2000 Index|
finance.yahoo.com - June 16 at 7:04 AM
|Zacks: Analysts Expect Kindred Biosciences, Inc. (KIN) to Announce -$0.29 EPS|
www.americanbankingnews.com - June 15 at 2:20 PM
|Kindred Biosciences, Inc. (KIN) Major Shareholder Purchases $101,818.15 in Stock|
www.americanbankingnews.com - June 12 at 7:34 PM
|Kindred Biosciences Inc (KIN) Raised to "Hold" at ValuEngine|
www.americanbankingnews.com - June 2 at 3:08 PM
|Kindred Biosciences Inc (KIN) Rating Reiterated by FBR & Co|
www.americanbankingnews.com - June 1 at 4:14 PM
|Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference|
finance.yahoo.com - May 30 at 10:22 AM
|BMO Capital Markets Reaffirms Hold Rating for Kindred Biosciences Inc (KIN)|
www.americanbankingnews.com - May 29 at 1:34 PM
|Kindred Biosciences Inc (KIN) Lifted to "Buy" at Zacks Investment Research|
www.americanbankingnews.com - May 27 at 7:36 PM
|Kindred Biosciences Inc (KIN) Short Interest Update|
www.americanbankingnews.com - May 25 at 11:05 AM
|Kindred Biosciences to Present at 7th Annual LD Micro Invitational|
finance.yahoo.com - May 24 at 11:16 AM
|Kindred Biosciences Inc (KIN) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - May 24 at 8:22 AM
|Kindred Biosciences Inc (KIN) Earns Outperform Rating from Analysts at FBR & Co|
www.americanbankingnews.com - May 24 at 7:20 AM
|Kindred Biosciences Inc (KIN) Major Shareholder Buys $1,059,169.08 in Stock|
www.americanbankingnews.com - May 15 at 10:34 PM
|Edited Transcript of KIN earnings conference call or presentation 3-May-17 8:30pm GMT|
finance.yahoo.com - May 6 at 6:12 PM
|Kindred Biosciences Inc (KIN) Announces Quarterly Earnings Results|
www.americanbankingnews.com - May 5 at 9:38 PM
|BMO Capital Markets Reiterates Hold Rating for Kindred Biosciences Inc (KIN)|
www.americanbankingnews.com - May 5 at 9:34 PM
|Kindred Biosciences (KIN) Given Daily Media Sentiment Rating of -0.12|
www.americanbankingnews.com - May 4 at 9:48 AM
|BRIEF-Kindred Biosciences announces Q1 loss per share $0.30|
www.reuters.com - May 4 at 1:16 AM
|Kindred Biosciences, Inc. 2017 Q1 - Results - Earnings Call Slides|
seekingalpha.com - May 4 at 1:16 AM
|Investor Network: Kindred Biosciences, Inc. to Host Earnings Call|
finance.yahoo.com - May 3 at 8:16 PM
|Kindred Biosciences Announces First Quarter 2017 Financial Results|
finance.yahoo.com - May 3 at 8:16 PM
|Kindred Bio reports 1Q loss|
finance.yahoo.com - May 3 at 8:16 PM
|Kindred Biosciences (KIN) Receives Daily Coverage Optimism Score of -0.12|
www.americanbankingnews.com - May 1 at 3:42 PM
|Kindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral for the Control of Fever in Horses|
finance.yahoo.com - May 1 at 1:03 PM
|Kindred Biosciences (KIN) Given Daily News Sentiment Rating of -0.12|
www.americanbankingnews.com - April 28 at 12:40 PM
Kindred Biosciences (KIN) Chart for Friday, August, 18, 2017